Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
Background. Thrombocytopenia is a common hematologic disorder observed in patients with chronic hepatitis C virus (HCV) infection. Combined peginterferon (PEG-INF) and ribavirin treatment may exacerbate thrombocytopenia in patients with HCV.Objective. The aim of this pilot clinical trial was to asse...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2011-10-01
|
Series: | Annals of Hepatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268119315133 |
id |
doaj-c3f1fabbff414f8daec13667aefbf87b |
---|---|
record_format |
Article |
spelling |
doaj-c3f1fabbff414f8daec13667aefbf87b2021-06-09T05:54:58ZengElsevierAnnals of Hepatology1665-26812011-10-01104458468Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirinGuillermo Cabrera Álvarez0Diana Gόmez-Galicia1Lourdes Rodríguez-Fragoso2Vicente Madrid Marina3Luis Cañedo Dorantes4Miguel Sánchez-Alemán5Nahum Méndez-Sánchez6Jorge Reyes Esparza7Departamento de Gastroenterologfa y Hepatologfa, Hospital General Regional UMF No. 1, Instituto Mexicano del Seguro Social. Cuernavaca, Morelos, México.Facultad de Farmacia, Universidad Autonoma del Estado de Morelos. Cuernavaca, Morelos, México.Facultad de Farmacia, Universidad Autonoma del Estado de Morelos. Cuernavaca, Morelos, México.Divisiόn de Enfermedades Infecciosas y Cáncer, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México.Facultad de Medicina, Universidad Autόnoma del Estado de Morelos. Cuernavaca, Morelos, México.Laboratorio de Infecciones de Transmisiόn Sexual, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México.Unidad de Hígado, Fundaciόn Clínica Médica Sur, México City, Mexico.Facultad de Farmacia, Universidad Autonoma del Estado de Morelos. Cuernavaca, Morelos, México.; Correspondence and reprint request:Background. Thrombocytopenia is a common hematologic disorder observed in patients with chronic hepatitis C virus (HCV) infection. Combined peginterferon (PEG-INF) and ribavirin treatment may exacerbate thrombocytopenia in patients with HCV.Objective. The aim of this pilot clinical trial was to assess the efficacy, tolerability and safety of Danazol in thrombocytopenia associated with PEG-INF and ribavirin treatment in patients with HCV.Material and methods. We included patients whose platelets were < 90,000/mm3 and who were undergoing antiviral treatment. Danazol (300–600 mg/day) was administered during and until the end of antiviral therapy [7.6 months (2 to 11 months)]. The monitoring was performed through platelet analysis and liver function tests. A viral load test was done at the beginning and end of treatment. Forty-nine patients receiving a combined therapy of PEG-INF, ribavirin and Danazol increased their platelet levels to 121,081/mm3 (46,000-216,000/mm3); 10.6% of patients gained > 100,000 platelets/mm3, and 71% of patients maintained their initial platelet levels. Sustained viral response (SVR) was achieved in 63% of patients. SVR rates were high in patients with genotype non 1 (78.7%) and decreased in patients with genotype 1 (60.1%). The increase in platelet levels was associated to an increase in fibrinogen levels and a decrease in the activity of ALT. By contrast, patients without SVR presented a delayed response to increased platelet levels and showed no significant improvement in liver function when they received Danazol.Conclusion. Danazol can be used along with PEG-INF and ribavirin to treat thrombocytopenia in patients with HCV.http://www.sciencedirect.com/science/article/pii/S1665268119315133PlateletsAntiviral therapyChronic hepatitisViral hepatitisSustained viral response |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Guillermo Cabrera Álvarez Diana Gόmez-Galicia Lourdes Rodríguez-Fragoso Vicente Madrid Marina Luis Cañedo Dorantes Miguel Sánchez-Alemán Nahum Méndez-Sánchez Jorge Reyes Esparza |
spellingShingle |
Guillermo Cabrera Álvarez Diana Gόmez-Galicia Lourdes Rodríguez-Fragoso Vicente Madrid Marina Luis Cañedo Dorantes Miguel Sánchez-Alemán Nahum Méndez-Sánchez Jorge Reyes Esparza Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin Annals of Hepatology Platelets Antiviral therapy Chronic hepatitis Viral hepatitis Sustained viral response |
author_facet |
Guillermo Cabrera Álvarez Diana Gόmez-Galicia Lourdes Rodríguez-Fragoso Vicente Madrid Marina Luis Cañedo Dorantes Miguel Sánchez-Alemán Nahum Méndez-Sánchez Jorge Reyes Esparza |
author_sort |
Guillermo Cabrera Álvarez |
title |
Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin |
title_short |
Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin |
title_full |
Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin |
title_fullStr |
Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin |
title_full_unstemmed |
Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin |
title_sort |
danazol improves thrombocytopenia in hcv patients treated with peginterferon and ribavirin |
publisher |
Elsevier |
series |
Annals of Hepatology |
issn |
1665-2681 |
publishDate |
2011-10-01 |
description |
Background. Thrombocytopenia is a common hematologic disorder observed in patients with chronic hepatitis C virus (HCV) infection. Combined peginterferon (PEG-INF) and ribavirin treatment may exacerbate thrombocytopenia in patients with HCV.Objective. The aim of this pilot clinical trial was to assess the efficacy, tolerability and safety of Danazol in thrombocytopenia associated with PEG-INF and ribavirin treatment in patients with HCV.Material and methods. We included patients whose platelets were < 90,000/mm3 and who were undergoing antiviral treatment. Danazol (300–600 mg/day) was administered during and until the end of antiviral therapy [7.6 months (2 to 11 months)]. The monitoring was performed through platelet analysis and liver function tests. A viral load test was done at the beginning and end of treatment. Forty-nine patients receiving a combined therapy of PEG-INF, ribavirin and Danazol increased their platelet levels to 121,081/mm3 (46,000-216,000/mm3); 10.6% of patients gained > 100,000 platelets/mm3, and 71% of patients maintained their initial platelet levels. Sustained viral response (SVR) was achieved in 63% of patients. SVR rates were high in patients with genotype non 1 (78.7%) and decreased in patients with genotype 1 (60.1%). The increase in platelet levels was associated to an increase in fibrinogen levels and a decrease in the activity of ALT. By contrast, patients without SVR presented a delayed response to increased platelet levels and showed no significant improvement in liver function when they received Danazol.Conclusion. Danazol can be used along with PEG-INF and ribavirin to treat thrombocytopenia in patients with HCV. |
topic |
Platelets Antiviral therapy Chronic hepatitis Viral hepatitis Sustained viral response |
url |
http://www.sciencedirect.com/science/article/pii/S1665268119315133 |
work_keys_str_mv |
AT guillermocabreraalvarez danazolimprovesthrombocytopeniainhcvpatientstreatedwithpeginterferonandribavirin AT dianagomezgalicia danazolimprovesthrombocytopeniainhcvpatientstreatedwithpeginterferonandribavirin AT lourdesrodriguezfragoso danazolimprovesthrombocytopeniainhcvpatientstreatedwithpeginterferonandribavirin AT vicentemadridmarina danazolimprovesthrombocytopeniainhcvpatientstreatedwithpeginterferonandribavirin AT luiscanedodorantes danazolimprovesthrombocytopeniainhcvpatientstreatedwithpeginterferonandribavirin AT miguelsanchezaleman danazolimprovesthrombocytopeniainhcvpatientstreatedwithpeginterferonandribavirin AT nahummendezsanchez danazolimprovesthrombocytopeniainhcvpatientstreatedwithpeginterferonandribavirin AT jorgereyesesparza danazolimprovesthrombocytopeniainhcvpatientstreatedwithpeginterferonandribavirin |
_version_ |
1721388764927885312 |